Value Assessment of Orphan Drugs in Switzerland and the EU

    31 Oct, 2018

    The Rare Disease Action Forum holds an international event on the topic of “value assessment of orphan drugs in Switzerland and the EU” on 31 October 2018 in Basel, Switzerland Experts from authorities, patient organizations and the industry will provide insights to assessment models for orphan drugs in Switzerland, the EU and specific individual countries such as Germany, Austria and France.

    A timely and predictable value assessment process for orphan drugs plays an important role in enabling access to treatment for patients with rare diseases. Due to the characteristics of rare diseases and related clinical trials (e.g. very low patient numbers, no active comparator) standard value assessment processes are especially challenging for orphan drugs. An additional hurdle to the reimbursement and access for patients is imposed by the fact that value assessments are mostly conducted at the time of marketing authorization without consideration of growing evidence from use in clinical practice.

    The RDAF event will give participants the opportunity to exchange knowledge and best practices on this topic.

    Continue reading

    RDAF hosts multi-stakeholder workshop on post-marketing registries

    The Rare Disease Action Forum (RDAF) will host a multi-stakeholder workshop on post-marketing registries for rare diseases on 21 September 2023 (14.00 – 19.00 CEST) in Basel, Switzerland. The workshop will gather stakeholders active in the rare disease field to...

    RDAF Newsletter

    We just released the first issue of the RDAF newsletter, which gives an overview of key policy developments and RDAF activities in the first half of the year. Highlights include: Overview of the latest policy developments relevant for the rare disease field...